Market Research Logo

Huntingtin (Huntington Disease Protein) - Pipeline Review, H1 2016

Huntingtin (Huntington Disease Protein) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Huntingtin (Huntington Disease Protein) - Pipeline Review, H1 2016’, provides in depth analysis on Huntingtin (Huntington Disease Protein) targeted pipeline therapeutics.

The report provides comprehensive information on the Huntingtin (Huntington Disease Protein), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Huntingtin (Huntington Disease Protein) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Huntingtin (Huntington Disease Protein)
  • The report reviews Huntingtin (Huntington Disease Protein) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Huntingtin (Huntington Disease Protein) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Huntingtin (Huntington Disease Protein) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Huntingtin (Huntington Disease Protein) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Huntingtin (Huntington Disease Protein)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Huntingtin (Huntington Disease Protein) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Huntingtin (Huntington Disease Protein) Overview
Therapeutics Development
Huntingtin (Huntington Disease Protein) - Products under Development by Stage of Development
Huntingtin (Huntington Disease Protein) - Products under Development by Therapy Area
Huntingtin (Huntington Disease Protein) - Products under Development by Indication
Huntingtin (Huntington Disease Protein) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Huntingtin (Huntington Disease Protein) - Products under Development by Companies
Huntingtin (Huntington Disease Protein) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Huntingtin (Huntington Disease Protein) - Companies Involved in Therapeutics Development
AFFiRiS AG
Ionis Pharmaceuticals, Inc.
Neurimmune Holding AG
nLife Therapeutics, S.L.
reMYND NV
Sangamo BioSciences, Inc.
UniQure N.V.
Voyager Therapeutics, Inc.
Vybion, Inc.
WAVE Life Sciences Ltd.
Huntingtin (Huntington Disease Protein) - Drug Profiles
AMT-130 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide 1 to Inhibit Huntingtin Protein for Huntington's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide 2 to Inhibit Huntingtin Protein for Huntington's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide to Inhibit HTT for Huntington's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotides to Inhibit Huntingtin Protein for Huntington's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Inhibit Huntingtin Protein for Huntington’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INT-41 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONIS-HTTRx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NI-302 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Huntingtin Protein for Huntington’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Huntingtin for Huntington's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VYHTT-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Huntingtin (Huntington Disease Protein) - Dormant Projects
Huntingtin (Huntington Disease Protein) - Featured News & Press Releases
Mar 22, 2016: uniQure Announces Preclinical Proof of Concept for Gene Therapy Approach in Huntington’s Disease
Jan 05, 2016: Ionis Pharmaceuticals Receives Orphan Drug Designation from the US FDA for IONIS-HTT Rx for the Treatment of Patients with Huntington Disease
Jul 21, 2015: Isis Pharmaceuticals Initiates Clinical Study of ISIS-HTT Rx in Patients With Huntington's Disease
Nov 19, 2014: Sangamo BioSciences Presents Study At Society For Neuroscience Meeting Demonstrating In Vivo Reversal Of Huntington's Disease Signs And Symptoms
Nov 12, 2013: Sangamo BioSciences Announces Presentation Of First Demonstration Of In Vivo Efficacy Of Novel ZFP Therapeutic For Huntington's Disease
Sep 03, 2013: Vybion’s Huntington Drug Neutralizes Critical Disease Driver
Oct 17, 2012: Sangamo BioSciences Announces First Presentation Of Data From ZFP Therapeutic For Huntington's Disease At 2012 Annual Meeting Of Society For Neuroscience
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Number of Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Pipeline by AFFiRiS AG, H1 2016
Pipeline by Ionis Pharmaceuticals, Inc., H1 2016
Pipeline by Neurimmune Holding AG, H1 2016
Pipeline by nLife Therapeutics, S.L., H1 2016
Pipeline by reMYND NV, H1 2016
Pipeline by Sangamo BioSciences, Inc., H1 2016
Pipeline by UniQure N.V., H1 2016
Pipeline by Voyager Therapeutics, Inc., H1 2016
Pipeline by Vybion, Inc., H1 2016
Pipeline by WAVE Life Sciences Ltd., H1 2016
Dormant Projects, H1 2016
List of Figures
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Top 10 Indication, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Type, H1 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report